当前地点:

EN

选择地点:

SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.

More

News & Events

More

2024/04/12

China National Medical Products Administration Granted Approval to SINOVAC's 5-dose Inactivated Poliomyelitis Vaccine

Beijing, China – April 12, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its Pol

R&D and Innovation

SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.

More

Our Vaccines

SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.

COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®

Validated by the World Health Organization's Emergency Use Listing ("EUL") Procedure on June 2, 2021

Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®

Validated by the World Health Organization's Emergency Use Listing ("EUL") Procedure on June 2, 2021

Influenza Vaccine Product Family

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent. Influenza Vaccine (Split Virion), Inactivated - Anflu®. Pandemic Influenza Vaccine (Inactivated, Adjuvanted) - Panflu®. H1N1 Influenza A Vaccine (Split Virion), Inactivated - Panflu.1®.

Mumps Vaccine, Live

Launched in 2012.